What is Zacks Research’s Forecast for TEVA Q1 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research increased their Q1 2025 earnings estimates for Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.48 per share for the quarter, up from their prior forecast of $0.46. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.34 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2025 earnings at $0.59 EPS, Q1 2026 earnings at $0.48 EPS and Q3 2026 earnings at $0.82 EPS.

Several other brokerages have also recently weighed in on TEVA. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Up 1.3 %

Teva Pharmaceutical Industries stock opened at $16.78 on Monday. The company has a fifty day simple moving average of $17.56 and a 200 day simple moving average of $17.35. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a 1-year low of $9.35 and a 1-year high of $19.31. The company has a market cap of $19.01 billion, a P/E ratio of -19.74, a price-to-earnings-growth ratio of 1.30 and a beta of 0.87.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. grew its position in shares of Teva Pharmaceutical Industries by 141.7% in the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock valued at $2,674,000 after purchasing an additional 90,920 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Sanctuary Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after buying an additional 664 shares in the last quarter. TCW Group Inc. bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $1,286,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 3.4% during the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after buying an additional 291,124 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.